Evidence map›Paper›PMID 37811006›Full record

ArticleCellular and molecular bioengineering2023

Engineering of Trophoblast Extracellular Vesicle-Delivering Hydrogels for Localized Tolerance Induction in Cell Transplantation.

Shivani C Hiremath, Jessica D Weaver

Open access · greenAbstract read
In one paragraph

Article in Cellular and molecular bioengineering, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Unlocking Transplant Tolerance with Biomaterials.Advanced healthcare materials · 2025
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Shivani C HiremathSchool of Biological and Health Systems Engineering, Arizona State University, 550 E. Orange St, Tempe, AZ 85281 USA.
Jessica D WeaverSchool of Biological and Health Systems Engineering, Arizona State University, 550 E. Orange St, Tempe, AZ 85281 USA.ORCID 0000-0001-7394-2443
Arizona State University · US

Funding

Immunosuppression-free transplantation through placental mimicryDP2AI169476 · NIAID · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI WEAVER, JESSICA DIANE · 2021 to 2024
$2.4M
Acquisition of a Leica TCS SP5 Laser Scanning Confocal MicroscopeS10RR027154 · NCRR · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI DUCH, CARSTEN JUERGEN · 2011 to 2011
$471k
Immunosuppression-free islet transplantation via localized immunomodulatory exosome tetheringR21AI151865 · NIAID · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI WEAVER, JESSICA DIANE · 2022 to 2023
$408k
NCRR NIH HHS S10 RR027154NIAID NIH HHS DP2 AI169476NIAID NIH HHS R21 AI151865
6 · The paper itself

Abstract

Purpose: The need for chronic systemic immunosuppression, which presents a host of acute risks to transplantation patients, remains the primary limitation for the translation of many cell therapies, such as insulin secreting cells for the treatment of type 1 diabetes. Trophoblasts are the professional tolerogenic cells of the placenta, and they secrete a range of soluble factors to induce antigen specific tolerance toward allogeneic fetal tissue during pregnancy, including extracellular vesicles. Here we develop a trophoblast extracellular vesicle-delivering hydrogel designed for sustained, localized tolerogenic factor delivery within a transplant site to induce localized tolerance toward cell grafts. Methods: We engineer a synthetic poly(ethylene glycol)-based hydrogel system to tether extracellular vesicles for sustained delivery, and compare this system to passive vesicle entrapment within an alginate hydrogel system. We characterize trophoblast extracellular vesicles for size and morphology, and evaluate vesicle tolerogenic protein content via proteomic analysis. We validate the retention and tethering of extracellular vesicles within the hydrogel systems via scanning electron and stimulated emission depletion microscopy, and measure vesicle release rate over time. Finally, we evaluate trophoblast extracellular vesicle influence on natural killer cell activation in vitro. Results: We isolated trophoblast extracellular vesicles and proteomics confirmed the presence of tolerogenic factors. We confirmed the presence of extracellular vesicles within hydrogel delivery vehicles, and synthetic hydrogels extended extracellular vesicle release relative to a passive hydrogel system. Finally, extracellular vesicles reduced natural killer cell activation in vitro, confirming the tolerogenic potential of hydrogel-delivered extracellular vesicles. Conclusions: This tolerogenic extracellular vesicle-delivering hydrogel platform designed for delivery within a transplant site could serve as an alternative to systemic immunosuppression in cell transplantation, potentially reducing the risks associated with cell therapies and widening the eligible patient population.

Indexed as

Cell therapyDrug deliveryExtracellular vesiclesHydrogelsImmune engineeringImmune toleranceTrophoblasts

Identifiers

PMID37811006
PMCPMC10550893
OpenAlexW4385945456

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.